Detection of soluble alpha 1 integrin in human serum

Citation
I. Bank et al., Detection of soluble alpha 1 integrin in human serum, J LA CL MED, 134(6), 1999, pp. 599-604
Citations number
32
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research General Topics
Journal title
JOURNAL OF LABORATORY AND CLINICAL MEDICINE
ISSN journal
00222143 → ACNP
Volume
134
Issue
6
Year of publication
1999
Pages
599 - 604
Database
ISI
SICI code
0022-2143(199912)134:6<599:DOSA1I>2.0.ZU;2-P
Abstract
An enzyme-linked immunosorbent assay (ELISA) for the detection and quantita tion of soluble alpha 1 beta 1 integrins (s alpha 1) in human serum samples was developed. Solid phase-bound anti-al integrin monoclonal antibody (mAb ) TS2/7 was used to capture sal,and mAb 1B3.1 was used to detect the immobi lized integrin. An extract of human placenta (PE) containing 340 ng/mL of V LA-1 molecules served as a positive control, and serum samples from normal donors and patients were assayed. Optimal binding of anti-al integrin mAb 1 B3.1,expressed as specific optical density (OD), was obtained when a 5 mu g /mL solution of anti-at integrin "capture" mAb TS2/7 was immobilized to the wells and the PE was added. Solutions of albumin or collagen, in contrast, did not result in binding, confirming the specificity of the assay for sat . Furthermore, the specific OD of the wells correlated directly with the co ncentration of PE. A concentration of sat above that of a 1:100 dilution of PE--that is, >3.4 ng/mL of integrin, in which the intra-assay correlation of variance was <5.7%, was found in 5 of 8, 3 of 8, and 6 of 9 serum sample s from normal individuals, patients with connective tissue diseases (CTD), and patients with liver diseases (LD), respectively. These results suggest, for the first time, that sat are present in healthy and diseased human ser um.